AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%
Last update at 2024-04-18T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -43.94500M | -27.79700M | -14.40000M |
| Minority interest | - | - | - |
| Net income | -43.09200M | -27.73300M | -14.40000M |
| Selling general administrative | 10.16M | 8.06M | 9.77M |
| Selling and marketing expenses | - | - | - |
| Gross profit | - | - | - |
| Reconciled depreciation | 0.00500M | 0.00100M | - |
| Ebit | -44.80300M | -27.83900M | -14.40000M |
| Ebitda | -44.79800M | -27.83800M | -14.40000M |
| Depreciation and amortization | 0.00500M | 0.00100M | - |
| Non operating income net other | -0.52800M | - | - |
| Operating income | -44.79800M | -27.83900M | -14.40000M |
| Other operating expenses | 44.80M | 27.84M | 14.40M |
| Interest expense | 0.84M | 0.04M | 0.00000M |
| Tax provision | - | - | - |
| Interest income | 0.84M | 0.06M | - |
| Net interest income | 0.84M | 0.06M | - |
| Extraordinary items | - | - | - |
| Non recurring | - | - | - |
| Other items | - | - | - |
| Income tax expense | -0.85300M | -0.06400M | - |
| Total revenue | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 44.80M | 27.84M | 14.40M |
| Cost of revenue | - | - | - |
| Total other income expense net | 0.85M | 0.04M | - |
| Discontinued operations | - | - | - |
| Net income from continuing ops | -44.48900M | -27.79700M | -14.40000M |
| Net income applicable to common shares | -43.94500M | -27.79700M | -14.40000M |
| Preferred stock and other adjustments | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 70.62M | 108.95M | 56.24M |
| Intangible assets | - | - | - |
| Earning assets | - | - | - |
| Other current assets | 2.25M | 1.66M | 0.05M |
| Total liab | 9.15M | 5.63M | 3.13M |
| Total stockholder equity | 61.47M | 103.32M | 53.10M |
| Deferred long term liab | - | - | 0.88M |
| Other current liab | 7.10M | 0.34M | 1.92M |
| Common stock | 0.00100M | 0.00100M | - |
| Capital stock | 0.00100M | 0.00100M | 55.80M |
| Retained earnings | -86.14200M | -42.19700M | -14.40000M |
| Other liab | - | - | - |
| Good will | - | - | - |
| Other assets | 0.03M | 0.03M | 0.88M |
| Cash | 10.78M | 66.35M | 55.32M |
| Cash and equivalents | - | - | - |
| Total current liabilities | 8.76M | 5.44M | 3.13M |
| Current deferred revenue | - | 3.74M | - |
| Net debt | -10.03500M | -65.82200M | -55.31600M |
| Short term debt | 0.36M | 0.34M | - |
| Short long term debt | - | - | - |
| Short long term debt total | 0.74M | 0.52M | - |
| Other stockholder equity | 148.30M | 36.73M | 11.71M |
| Property plant equipment | 0.00900M | 0.54M | - |
| Total current assets | 69.84M | 108.38M | 55.36M |
| Long term investments | 0.03M | - | - |
| Net tangible assets | 61.85M | 103.32M | -2.69200M |
| Short term investments | 56.81M | 40.38M | - |
| Net receivables | - | - | - |
| Long term debt | - | - | - |
| Inventory | - | - | - |
| Accounts payable | 1.31M | 1.03M | 1.21M |
| Total permanent equity | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - |
| Accumulated other comprehensive income | -0.69200M | -0.16400M | - |
| Additional paid in capital | - | - | - |
| Common stock total equity | 0.00100M | - | - |
| Preferred stock total equity | - | - | - |
| Retained earnings total equity | -86.14200M | - | - |
| Treasury stock | - | - | - |
| Accumulated amortization | - | - | - |
| Non currrent assets other | 0.03M | 0.03M | 0.88M |
| Deferred long term asset charges | - | - | - |
| Non current assets total | 0.78M | 0.57M | 0.88M |
| Capital lease obligations | 0.74M | 0.52M | - |
| Long term debt total | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -17.06400M | -40.70000M | -40.70000M |
| Change to liabilities | 1.38M | -0.18500M | 1.21M |
| Total cashflows from investing activities | -17.06400M | -40.71600M | -40.71600M |
| Net borrowings | -0.44400M | - | - |
| Total cash from financing activities | -0.44400M | 76.45M | 58.76M |
| Change to operating activities | 2.84M | 1.15M | 1.24M |
| Net income | -43.94500M | -27.79700M | -14.40000M |
| Change in cash | -55.57100M | 11.03M | 55.32M |
| Begin period cash flow | 66.35M | 55.32M | 0.00000M |
| End period cash flow | 10.78M | 66.35M | 55.32M |
| Total cash from operating activities | -38.06300M | -24.70500M | -3.44200M |
| Issuance of capital stock | 0.00000M | 84.77M | 56.00M |
| Depreciation | 0.00500M | 0.00100M | 0.00100M |
| Other cashflows from investing activities | - | - | - |
| Dividends paid | - | - | - |
| Change to inventory | - | - | - |
| Change to account receivables | - | - | - |
| Sale purchase of stock | 0.00000M | -0.00100M | - |
| Other cashflows from financing activities | -0.44400M | -8.32200M | 58.76M |
| Change to netincome | 2.66M | 2.12M | 8.51M |
| Capital expenditures | 0.00000M | 0.02M | 0.02M |
| Change receivables | - | - | - |
| Cash flows other operating | 1.74M | - | - |
| Exchange rate changes | - | - | - |
| Cash and cash equivalents changes | -55.57100M | - | - |
| Change in working capital | 3.12M | 0.97M | 2.45M |
| Stock based compensation | 2.66M | 1.97M | 8.51M |
| Other non cash items | 0.10M | 0.16M | - |
| Free cash flow | -38.06300M | -24.72100M | -3.44200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| LBPH Longboard Pharmaceuticals Inc |
1.01 5.94% | 18.01 | - | - | - | 2.50 | -1.4083 | |
| NVO Novo Nordisk A/S |
-1.78 1.43% | 122.75 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.344 1.08% | 122.81 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.38 0.10% | 393.48 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-1.042 1.18% | 86.92 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
4275 Executive Square, La Jolla, CA, United States, 92037
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin R. Lind | Pres, CEO, Sec. & Director | 1976 |
| Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer | 1974 |
| Mr. Chadwick J. Orevillo MPH | VP & Head of Operations | NA |
| Megan E. Knight | Head of Investor Relations | NA |
| Mr. Steven W. Spector J.D. | Head of Bus. Devel. & Gen. Counsel | 1965 |
| Dr. Anne M. Danks | VP & Head of Preclinical Devel. | NA |
| Dr. Jodi Parsons | VP & Head of Regulatory Affairs | NA |
| Dr. Randall E. Kaye M.D. | Chief Medical Officer | 1962 |
| Gus Cardenas | VP & Head of Quality Assurance | NA |
| Dr. Marco Peters Ph.D. | VP & Head of Translational Science | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...